CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology is based in IRVINE, Calif.
| Revenue (Most Recent Fiscal Year) | $0.20M |
| Net Income (Most Recent Fiscal Year) | $-48.61M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 3059.31 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.44 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -10642.98% |
| Net Margin (Trailing 12 Months) | -10642.98% |
| Return on Equity (Trailing 12 Months) | -18.97% |
| Return on Assets (Trailing 12 Months) | -15.36% |
| Current Ratio (Most Recent Fiscal Quarter) | 35.32 |
| Quick Ratio (Most Recent Fiscal Quarter) | 35.32 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-1.94 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.30 |
| Earnings per Share (Most Recent Fiscal Year) | $-15.65 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 76.04M |
| Free Float | -- |
| Market Capitalization | $2.09B |
| Average Volume (Last 20 Days) | 0.42M |
| Beta (Past 60 Months) | -- |
| Percentage Held By Insiders (Latest Annual Proxy Report) | -- |
| Percentage Held By Institutions (Latest 13F Reports) | 26.56% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |